Takeda traded at 5,815.00 this Wednesday March 25th, increasing 152.00 or 2.68 percent since the previous trading session. Looking back, over the last four weeks, Takeda gained 1.47 percent. Over the last 12 months, its price rose by 28.25 percent. Looking ahead, we forecast Takeda to be priced at 5,519.40 by the end of this quarter and at 4,836.06 in one year, according to Trading Economics global macro models projections and analysts expectations.
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.